| Literature DB >> 33106674 |
Jeffrey Seow1, Carl Graham1, Blair Merrick2, Sam Acors1, Suzanne Pickering1, Kathryn J A Steel3, Oliver Hemmings4, Aoife O'Byrne3, Neophytos Kouphou1, Rui Pedro Galao1, Gilberto Betancor1, Harry D Wilson1, Adrian W Signell1, Helena Winstone1, Claire Kerridge1, Isabella Huettner1, Jose M Jimenez-Guardeño1, Maria Jose Lista1, Nigel Temperton5, Luke B Snell2, Karen Bisnauthsing2, Amelia Moore6, Adrian Green6, Lauren Martinez6, Brielle Stokes6, Johanna Honey6, Alba Izquierdo-Barras6, Gill Arbane7, Amita Patel2, Mark Kia Ik Tan2, Lorcan O'Connell2, Geraldine O'Hara2, Eithne MacMahon2, Sam Douthwaite2, Gaia Nebbia2, Rahul Batra2, Rocio Martinez-Nunez1, Manu Shankar-Hari1,7, Jonathan D Edgeworth1,2, Stuart J D Neil1, Michael H Malim1, Katie J Doores8.
Abstract
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33106674 PMCID: PMC7610833 DOI: 10.1038/s41564-020-00813-8
Source DB: PubMed Journal: Nat Microbiol ISSN: 2058-5276 Impact factor: 17.745